ArticleHIV medicine2026
Informal PrEP use in Greece: The long, hard road to formal programmatic implementation.
Article in HIV medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Informal PrEP use in Greece: The long, hard road to formal programmatic implementation.HIV medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
objectivesPre-exposure prophylaxis (PrEP) with antiretroviral drugs (ARVs) is a highly effective HIV prevention strategy. Although the European Medicines Agency approved oral PrEP in 2016 and the World Health Organization (WHO) has since recommended simplified and person-centred delivery models, implementation remains inconsistent across Europe. In Greece, national PrEP guidelines were issued in 2022, but public sector access has not yet been established.
methodsWe report on informal PrEP use in 2024 among men who have sex with men (MSM) and transgender women (TGW) attending a private sexual health clinic in Athens.
resultsAmong 547 MSM and TGW (mean age 36 ± 9 years), 308 (56.3%) were suitable for PrEP, 47 were already on PrEP and 134 initiated PrEP using generic formulations purchased online (39.6% daily, 60.4% on demand). Among 181 individuals on PrEP, 79.6% were retained in care, and no seroconversions were recorded over 2423 person-months of follow-up. Sexually transmitted infections (STIs) were diagnosed in 30.3%, indicating elevated HIV risk. Barriers to uptake included cost, online procurement concerns and limited awareness.
conclusionsThese findings highlight the urgent need for formally implemented, accessible PrEP services in Greece. Integration within broader sexual health frameworks, aligned with WHO recommendations, is essential to improve access, monitoring and HIV prevention in high-risk populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.